Subcutaneous infliximab CT-P13 Remsima®SC
Pre-clinicalUNKNOWN 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammatory Bowel Diseases
Conditions
Inflammatory Bowel Diseases
Trial Timeline
Sep 6, 2021 → Sep 30, 2024
NCT ID
NCT04990258About Subcutaneous infliximab CT-P13 Remsima®SC
Subcutaneous infliximab CT-P13 Remsima®SC is a pre-clinical stage product being developed by Celltrion for Inflammatory Bowel Diseases. The current trial status is unknown. This product is registered under clinical trial identifier NCT04990258. Target conditions include Inflammatory Bowel Diseases.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04990258 | Pre-clinical | UNKNOWN |
Competing Products
20 competing products in Inflammatory Bowel Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Infliximab + Infliximab + Infliximab | Celltrion | Approved | 85 |
| CT-P13 | Celltrion | Phase 3 | 77 |
| Infliximab subcutaneous + Immunosuppressive Agents | Celltrion | Phase 3 | 77 |
| fidaxomicin | Astellas Pharma | Approved | 85 |
| Eribulin + Adriamycin + Cyclophosphamide | Eisai | Phase 2 | 52 |
| E6007 + E6007 + E6007 + E6007 + E6007 + E6007 | Eisai | Phase 1 | 33 |
| Placebo + MORF-057 | Eli Lilly | Phase 2 | 52 |
| Baricitinib + Baricitinib | Eli Lilly | Phase 2 | 52 |
| LY3114062 SC + Placebo + LY3114062 IV | Eli Lilly | Phase 1 | 33 |
| MORF-057 + Placebo | Eli Lilly | Phase 2 | 52 |
| MORF-057 | Eli Lilly | Phase 2 | 52 |
| LY3009104 | Eli Lilly | Phase 1 | 33 |
| HRF2105 patch + Loxoprofen patch + placebo | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Risankizumab | AbbVie | Approved | 85 |
| GC012F Injection infusion | AstraZeneca | Phase 1 | 33 |
| AZD6793 + Placebo | AstraZeneca | Phase 1 | 33 |
| Human Papillomavirus Vaccine | Merck | Approved | 85 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Gardasil vaccine | Merck | Pre-clinical | 23 |
| Bezlotoxumab | Merck | Approved | 85 |
Other Products from Celltrion
Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85